Skip to content
2000
Volume 20, Issue 4
  • ISSN: 1574-8863
  • E-ISSN: 2212-3911

Abstract

Background

Tumor necrosis factor alpha (TNF-α) inhibitors, such as adalimumab, have significantly advanced the treatment of inflammatory diseases. However, these therapies are associated with various cutaneous adverse reactions.

Case Presentation

We describe two rare instances of isolated facial hyperpigmentation induced by adalimumab. Both patients presented with asymptomatic, isolated brown macules on the cheeks following adalimumab treatment for ankylosing spondylitis. The hyperpigmentation appeared shortly after starting the medication in both cases. In one case, the hyperpigmentation persisted despite stopping the medication, while in the second case, it completely resolved within one month after discontinuation. However, in the second patient, the hyperpigmentation recurred after switching to certolizumab, another TNF-α inhibitor. No skin biopsies were performed, and both patients were otherwise healthy, with normal laboratory evaluations.

Conclusion

Hyperpigmentation is an uncommon adverse reaction of this class of drugs, with only a few reported cases in the literature. The recurrence of hyperpigmentation after switching to another TNF-α agent, certolizumab, further suggests that this reaction may be a class effect, adding new insights into the spectrum of cutaneous side effects associated with TNF-α inhibitors. Clinicians should consider this potential side effect in patients presenting with hyperpigmentation, and sun protection should be recommended as a preventive measure.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863357040241025051122
2024-10-31
2025-07-28

  • From This Site

    /content/journals/cds/10.2174/0115748863357040241025051122
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. LeoneG.M. ManganoK. PetraliaM.C. NicolettiF. FagoneP. Past, present and (foreseeable) future of biological anti-TNF alpha therapy.J. Clin. Med.2023124163010.3390/jcm1204163036836166
     [Google Scholar]
  2. LopetusoL.R. CuomoC. MigniniI. GasbarriniA. PapaA. Focus on anti-tumour necrosis factor (tnf)-α-related autoimmune diseases.Int. J. Mol. Sci.2023249818710.3390/ijms2409818737175894
     [Google Scholar]
  3. MocciG. MarzoM. PapaA. ArmuzziA. GuidiL. Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease.J. Crohn’s Colitis201371076977910.1016/j.crohns.2013.01.00923453887
     [Google Scholar]
  4. AuM. HeddleG. YoungE. RyanE. GrafS. TeeD. PhilpottH. Anti-tumour necrosis factor-induced skin rashes in inflammatory bowel disease: A systematic review and evidence-based management algorithm.Intern. Med. J.202353101854186510.1111/imj.1585935760771
     [Google Scholar]
  5. HernándezM.V. SanmartíR. CañeteJ.D. DescalzoM.A. AlsinaM. CarmonaL. Gomez-ReinoJ.J. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases.Arthritis Care Res.201365122024203110.1002/acr.2209623926075
     [Google Scholar]
  6. LindhausC. TittelbachJ. ElsnerP. Cutaneous side effects of TNF-alpha inhibitors.J. Dtsch. Dermatol. Ges.201715328128828252861
     [Google Scholar]
  7. BlombergM. ZachariaeC.O.C. GrønhøjF. Hyperpigmentation of the face following adalimumab treatment.Acta Derm. Venereol.200989554654710.2340/00015555‑069719734995
     [Google Scholar]
  8. EllisC.R. AzmatC.E. Adalimumab.StatPearls.Treasure Island, FLStatPearls Publishing2024
     [Google Scholar]
  9. KamalM.E. WeridaR.H. RadwanM.A. Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients.Inflammopharmacol.2024323259326910.1007/s10787‑024‑01508‑w
     [Google Scholar]
  10. DownesM.R. PrendivilleS. KielyC. LenaneP. MulliganN. Cutaneous reactions to adalimumab administration.Ir. Med. J.2011104412212321675098
     [Google Scholar]
  11. WangJ. YinX. YuL. ChengW. WangL. ZhaoB. LiZ. JingX. Delayed cutaneous hypersensitivity reactions following the use of infliximab or adalimumab in patients with coronavirus disease 2019.J. Med. Virol.2023952e2851810.1002/jmv.2851836700393
     [Google Scholar]
  12. BeuthienW. MellinghoffH.U. von KempisJ. Skin reaction to adalimumab.Arthritis Rheum.20045051690169210.1002/art.2015515146441
     [Google Scholar]
  13. GilF. AndradeI. AranhaJ. Hyperpigmentation as a rare side effect of adalimumab.Int. J. Dermatol.2021603e105e10610.1111/ijd.1526833107034
     [Google Scholar]
  14. BégaudB. LagierG. VincensM. LefebureB. FrêlonJ.H. Imputabilité des effets indésirables des médicaments.Therapie1985401111184002188
     [Google Scholar]
  15. CestariT.F. DantasL.P. BozaJ.C. Acquired hyperpigmentations.An. Bras. Dermatol.2014891112510.1590/abd1806‑4841.2014235324626644
     [Google Scholar]
  16. WangR.F. KoD. FriedmanB.J. LimH.W. MohammadT.F. Disorders of hyperpigmentation. Part I. Pathogenesis and clinical features of common pigmentary disorders.J. Am. Acad. Dermatol.202388227128810.1016/j.jaad.2022.01.05135151757
     [Google Scholar]
  17. NautiyalA. WairkarS. Management of hyperpigmentation: Current treatments and emerging therapies.Pigment Cell Melanoma Res.20213461000101410.1111/pcmr.1298633998768
     [Google Scholar]
  18. YamamotoN. DejimaA. HasataniK. Minocycline-induced hyperpigmentation in a patient with prurigo pigmentosa.BMJ Case Rep.2021146e24436510.1136/bcr‑2021‑24436534140334
     [Google Scholar]
  19. LipskerD. LenormandC. Hyperpigmentations.Ann. Dermatol. Venereol.20191461066668210.1016/j.annder.2019.05.00531537319
     [Google Scholar]
  20. DasS. Hyperpigmentation in Dermatologic Disorders.2022
     [Google Scholar]
  21. SyderN.C. QuarshieC. ElbulukN. Disorders of facial hyperpigmentation.Dermatol. Clin.202341339340510.1016/j.det.2023.02.00537236709
     [Google Scholar]
  22. ThakurV. BakshiS. BishnoiA. Adalimumab-induced photosensitivity and oral erosions in rheumatoid arthritis.Postgrad. Med. J.202096114063163210.1136/postgradmedj‑2019‑13732931896550
     [Google Scholar]
  23. AlrashidiA. RhodesL.E. SharifJ.C.H. KreeshanF.C. FarrarM.D. AhadT. Systemic drug photosensitivity—Culprits, impact and investigation in 122 patients.Photodermatol. Photoimmunol. Photomed.202036644145110.1111/phpp.1258332564400
     [Google Scholar]
  24. GarcíaR.M. MolinaS. Drug-induced hyperpigmentation: Review and case series.J. Am. Board Fam. Med.201932462863810.3122/jabfm.2019.04.18021231300585
     [Google Scholar]
  25. EichenfieldD.Z. CohenP.R. Amitriptyline-induced cutaneous hyperpigmentation: case report and review of psychotropic drug-associated mucocutaneous hyperpigmentation.Dermatol Online J.201622213030/qt3455571b10.5070/D3222030090
     [Google Scholar]
  26. NahhasA.F. BraunbergerT.L. HamzaviI.H. An update on drug-induced pigmentation.Am. J. Clin. Dermatol.2019201759610.1007/s40257‑018‑0393‑230374894
     [Google Scholar]
  27. KrauseW. Drug-induced hperpigemntation: a systematic review.J. Dtsch. Dermatol. Ges.201311764465110.1111/ddg.1204223650908
     [Google Scholar]
  28. BertrandA.S. CostaK. DereureO. PallureV. Une pigmentation atypique et inhabituelle du visage sous adalimumab.Ann. Dermatol. Venereol.201714412S332S33310.1016/j.annder.2017.09.565
     [Google Scholar]
  29. PandaP.K. SharawatI.K. YadavR. Methotrexate-induced hyperpigmentation over sun-exposed area.J. Clin. Rheumatol.2021277e287e28810.1097/RHU.000000000000142832541613
     [Google Scholar]
  30. AlsisiG.G. AlsisiM.H. AlhowaishA.K. AlshammariW.S. Erythema dyschromicum perstans after adalimumab treatment.Cureus20221412e3226436620779
     [Google Scholar]
  31. GarcovichS. BurlandoM. RongiolettiF. GarcovichA. ParodiA. AmerioP. Cutaneous drug eruption with an interface dermatitis pattern due to anti-tumour necrosis factor-alpha agents: A relevant class-effect.Acta Derm. Venereol.201090331131210.2340/00015555‑083920526559
     [Google Scholar]
  32. SinghM. MansuriM.S. KadamA. PalitS.P. DwivediM. LaddhaN.C. BegumR. Tumor Necrosis Factor-alpha affects melanocyte survival and melanin synthesis via multiple pathways in vitiligo.Cytokine202114015543210.1016/j.cyto.2021.15543233517195
     [Google Scholar]
  33. ZattraE. FortinaA.B. BordignonM. PiasericoS. AlaibacM. Immunosuppression and melanocyte proliferation.Melanoma Res.2009192636810.1097/CMR.0b013e328322fc2019194340
     [Google Scholar]
  34. BardazziF. MagnanoM. AntonucciV.A. BalestriR. SgubbiP. PatriziA. Lentigines in previous psoriatic plaques in a patient treated with infliximab.Eur. J. Dermatol.201222569869910.1684/ejd.2012.181822940696
     [Google Scholar]
/content/journals/cds/10.2174/0115748863357040241025051122
Loading
Facial Hyperpigmentation Following Adalimumab
Curr Drug Saf 20, 504 (2025); https://doi.org/10.2174/0115748863357040241025051122
/content/journals/cds/10.2174/0115748863357040241025051122
/content/journals/cds/10.2174/0115748863357040241025051122
Loading

Data & Media loading...


  • Article Type:     Case Report
Keyword(s): Adalimumab; adverse effects; cutaneous adverse reaction; drug-induced hyperpigmentation; pigmentary disorders; TNF-α inhibitors

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test